Beam Therapeutics is trading 4.61% lower at $26.58 after third-quarter results missed analyst estimates. - The company reported a $1.28-per-share loss and $0.307 million in revenue, versus analyst estimates of a $1.17-per-share loss and $9.96 million in revenue. - A November 5 report renewed attention to the earnings miss and widened loss. Beam maintained its year-end risto-cel BLA filing target and said its cash runway extends into mid-2029. - The broader market is sharply lower, but biotech-sector context is positive.